Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
193.60
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
...
21
22
23
24
25
26
27
28
29
...
39
40
Next >
Bear Of The Day: Biogen
April 04, 2022
Biogen’s MS revenues were $1.79 billion in the reporter quarter, including Ocrevus royalties, which declined 1% (both actual and constant currency basis) year over year.
Via
Talk Markets
3 Undervalued Stocks to Buy This Week
March 30, 2022
Here are the three undervalued stocks to buy this week.
Via
Talk Markets
Amylyx Pharmaceuticals Stock Crashes As FDA Doubts Its ALS Treatment
March 28, 2022
Amylyx Pharmaceuticals could face an uphill battle for its ALS treatment this week.
Via
Investor's Business Daily
Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints
March 28, 2022
Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have
Via
Benzinga
Why I Sold Kohl’s Corporation Despite Possible Buyout Deal
March 22, 2022
2022 has been a headline-packed for Kohl’s and KSS stock. But after a closer look at my portfolio grader, this is why it was time to sell.
Via
InvestorPlace
Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab
March 22, 2022
In the partnership that spawned aducanumab, Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) have
Via
Benzinga
Biogen Shares Aduhelm Data In Alzheimer's Disease At 128 Weeks
March 16, 2022
Via
Benzinga
Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact
March 15, 2022
Via
Benzinga
Biogen Says It Cracked The Alzheimer's Puzzle, But Investors May Need More Evidence
March 16, 2022
Patients who received Aduhelm for over two years showed declines in two markers.
Via
Investor's Business Daily
News-Filled Day
March 15, 2022
The price of oil fell to below $100/oz on the prospect of lower demand from the PRC.
Via
Talk Markets
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
March 15, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Hopes For A Peace Accord
March 14, 2022
The winner today was BioNTech up 14.89% on hopes for new sales for the Covid-19 variant.
Via
Talk Markets
Biogen Posts New Updates Across its Spinraza SMA Research Program
March 14, 2022
Biogen Inc (NASDAQ: BIIB) announced new data and updates from its Spinraza (nusinersen) and spinal muscular atrophy (SMA) research program, including the ASCEND, RESPOND and...
Via
Benzinga
Bristol Myers, Eli Lilly And 2 Others Prove You Can Still Make Money In Medical Stocks
March 11, 2022
These four medical stocks are outperforming the lousy market for health care investors.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2022
March 08, 2022
Upgrades According to Janney Montgomery Scott, the prior rating for Wintrust Financial Corp (NASDAQ:WTFC) was changed from Neutral to Buy. Wintrust Finl earned $1.58 in the fourth...
Via
Benzinga
10 Biggest Price Target Changes For Tuesday
March 08, 2022
Raymond James cut the price target on Ciena Corporation (NYSE: CIEN) from $80 to $75. Ciena shares fell 10.9% to close at $58.76 on Monday. Telsey Advisory Group cut Capri...
Via
Benzinga
The Daily Biotech Pulse: Ocugen Faces Regulatory Setback, vTv CEO Quits, Biogen-Eisai Make Headway With Second Alzheimer's Antibody Treatment In Japan
March 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck's Keytruda Evaluated In Combination With Microbiome Therapeutic In...
Via
Benzinga
Why This Analyst Sees Roughly 20% Upside In This Large-Cap Biopharma
March 03, 2022
Biogen Inc (NASDAQ: BIIB) shares are now trading notably off their all-time high of $468.55 hit on June 7, achieved on the back of Aduhelm approval. An analyst at RBC...
Via
Benzinga
Expert Ratings For Biogen
March 03, 2022
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 7...
Via
Benzinga
Biogen Has An $8 Billion Alzheimer's Opportunity — Will It Materialize?
March 03, 2022
A few key things have to go right for Biogen to snag a definitive win in Alzheimer's.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2022
March 03, 2022
Upgrades For Douglas Emmett Inc (NYSE:DEI), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the fourth quarter, Douglas Emmett had an EPS of $0.48,...
Via
Benzinga
10 Biggest Price Target Changes For Thursday
March 03, 2022
Piper Sandler cut the price target on Bright Health Group, Inc. (NYSE: BHG) from $10 to $5. Bright Health shares rose 3.2% to $2.59 in pre-market trading.
Via
Benzinga
How Many Stocks Are Down From Their Pre-COVID Levels?
February 21, 2022
On February 19th, 2020, the S&P 500 made its last closing high prior to all hell breaking loose for the next month.
Via
Talk Markets
Stocks That Hit 52-Week Lows On Thursday
February 17, 2022
On Thursday, 147 companies achieved new lows for the year. Significant Points From Today's 52-Week Lows: PayPal Holdings (NASDAQ:PYPL) was the biggest company...
Via
Benzinga
Why A Biogen-Sage Drug Flopped — And Could Still Be Approved
February 16, 2022
The companies tested a combination of zuranolone and depression drugs.
Via
Investor's Business Daily
Sage Therapeutics - Biogen Partnered Depression Drug Meets Main Goal In Late-stage Study
February 16, 2022
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) said zuranolone combined with a standard of care antidepressant met the primary goal of showing...
Via
Benzinga
US Senate Narrowly Votes In Favor Of Biden's Nominee Robert Califf To Lead FDA For Second Time
February 16, 2022
By a narrow vote of 50-46, the Senate has confirmed Robert Califf to run the FDA. Califf, who previously served as the FDA commissioner from February 2016 to January...
Via
Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
February 16, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following...
Via
Benzinga
Revisiting the Biggest Winners and Losers Since the COVID Crash Low
February 16, 2022
A look at how the average stock that’s currently in the S&P 1500 has done since the Covid crash low by sector.
Via
Talk Markets
Large Cap Biopharma- Well Positioned For Choppy Markets
February 14, 2022
If the past week is any indicator large-cap biopharma stocks are a good place to hide from the turbulence of 2022 markets.
Via
Talk Markets
< Previous
1
2
...
21
22
23
24
25
26
27
28
29
...
39
40
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.